These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
343 related articles for article (PubMed ID: 15060531)
1. Cutting the cost of drug development? Rawlins MD Nat Rev Drug Discov; 2004 Apr; 3(4):360-4. PubMed ID: 15060531 [No Abstract] [Full Text] [Related]
2. America's other drug problem: how the drug industry distorts medicine and politics. Relman AS; Angell M New Repub; 2002 Dec; 227(25):27-41. PubMed ID: 12561803 [No Abstract] [Full Text] [Related]
3. Costing drug development. Nat Rev Drug Discov; 2003 Apr; 2(4):247. PubMed ID: 12680358 [No Abstract] [Full Text] [Related]
4. Medicine. A portfolio model of drug development for tuberculosis. Glickman SW; Rasiel EB; Hamilton CD; Kubataev A; Schulman KA Science; 2006 Mar; 311(5765):1246-7. PubMed ID: 16513969 [No Abstract] [Full Text] [Related]
6. New estimates of drug development costs. Frank RG J Health Econ; 2003 Mar; 22(2):325-30. PubMed ID: 12606149 [No Abstract] [Full Text] [Related]
7. Who pays what in drug development. Love J Nature; 1999 Jan; 397(6716):202. PubMed ID: 9930689 [No Abstract] [Full Text] [Related]
8. A new approach to drug development. Brown S N Engl J Med; 2006 Nov; 355(19):2045; author reply 2046. PubMed ID: 17099948 [No Abstract] [Full Text] [Related]
9. Rising costs hold up drug discovery. Miller HI Nature; 1998 Oct; 395(6705):835. PubMed ID: 9804407 [No Abstract] [Full Text] [Related]
10. The state of innovation in drug development. Kola I Clin Pharmacol Ther; 2008 Feb; 83(2):227-30. PubMed ID: 18202690 [TBL] [Abstract][Full Text] [Related]
11. The price of innovation: new estimates of drug development costs. DiMasi JA; Hansen RW; Grabowski HG J Health Econ; 2003 Mar; 22(2):151-85. PubMed ID: 12606142 [TBL] [Abstract][Full Text] [Related]
12. Medical ethics, research and the pharmaceutical industry. Abud-Mendoza C Reumatol Clin; 2012; 8(5):233-5. PubMed ID: 22608694 [No Abstract] [Full Text] [Related]
13. [The course of the drug, clinical research and commercialization. Constraints, obstacles, delays and costs]. Giri I; Rouillon F Encephale; 2006 Oct; 32(5 Pt 3):S858-60. PubMed ID: 17119487 [No Abstract] [Full Text] [Related]
14. Surviving the blockbuster syndrome. Service RF Science; 2004 Mar; 303(5665):1796-9. PubMed ID: 15031490 [No Abstract] [Full Text] [Related]
15. The economics of drug discovery and the ultimate valuation of pharmacotherapies in the marketplace. Sollano JA; Kirsch JM; Bala MV; Chambers MG; Harpole LH Clin Pharmacol Ther; 2008 Aug; 84(2):263-6. PubMed ID: 18547999 [TBL] [Abstract][Full Text] [Related]
20. [Clinical drug research in Denmark--as effective, harmless and cheap as possible]. Højgaard L Ugeskr Laeger; 1994 Feb; 156(6):784-6. PubMed ID: 8016979 [No Abstract] [Full Text] [Related] [Next] [New Search]